Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance
Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance
复制标题
DOI：
10.3748/wjg.v17.i16.2113
复制
发表时间：
2011-04-28
影响因子：
4.3
通讯作者：
Chen, Miin-Fu
中科院分区：
文献类型：
--
作者：
Chen, Yen-Yang;Yeh, Chun-Nan;Chen, Miin-Fu
目的：报告舒尼替尼的疗效和安全性的初步结果，在台湾的胃肠道造口肿瘤（GIST）患者面临伊马替尼甲磺酸盐（IM）不耐受或failure.METHODS的管理：2001年至2010年5月，199名台湾转移性GIST患者在长庚纪念医院治疗。其中，23例（11.6%）接受舒尼替尼的患者进行了调查。结果：16名男性和7名女性患者，中位年龄为59岁（范围：24-83岁）接受舒尼替尼。22例GIST患者因IM失败而改用舒尼替尼，1例因不耐受而改用舒尼替尼。舒尼替尼给药的中位持续时间为6.0个月（范围：2-29个月）。临床获益率为65.2% [2例完全缓解（CR），4例部分缓解（PR），9例疾病稳定（SD）; 15/23]。在12例携带kit基因外显子11突变的患者中，临床获益率（CR、PR和SD）为75.0%，6例肿瘤携带kit外显子9突变的患者的临床获益率为50.0%（不显著，P = 0.344）。无进展生存期（PFS）和总生存期（OS）在GIST具有野生型、KIT外显子9或KIT外显子11突变的患者之间没有差异。手足综合征是最常见的III级不良反应原因（26.1%），其次是贫血（17.4%）和中性粒细胞减少（13.0%）。在平均7.5个月的后续舒尼替尼使用后，中位PFS和OS的这23个GIST患者舒尼替尼治疗后分别为8.4和14.1 mo，either.CONCLUSION：舒尼替尼似乎是一种有效的治疗与IM耐药/不耐受的GIST台湾和诱导超过50%的台湾晚期GIST患者的持续临床获益。(C)2011年百世登。All rights reserved.
AIM: To report preliminary results of the efficacy and safety of sunitinib in the management of Taiwanese gastrointestinal stomal tumors (GIST) patients facing imatinib mesylate (IM) intolerance or failure.METHODS: Between 2001 and May 2010, 199 Taiwanese patients with metastatic GIST were treated at Chang Gung Memorial Hospital. Among them, 23 (11.6%) patients receiving sunitinib were investigated.RESULTS: Sixteen male and 7 female patients with a median age of 59 years (range: 24-83 years) received sunitinib. Twenty-two GIST patients changed to sunitinib because of IM failure and 1 because of intolerance. The median duration of sunitinib administration was 6.0 mo (range: 2-29 mo). The clinical benefit was 65.2% [2 complete response (CR), 4 partial response (PR), and 9 stationary disease (SD); 15/23]. In 12 patients harboring mutations of the kit gene at exon 11, the clinical benefit rate (CR, PR, and SD) was 75.0% and 6 patients with tumors containing kit exon 9 mutations had a clinical benefit of 50.0% (not significant, P = 0.344). The progression free survival (PFS) and overall survival (OS) did not differ between patients whose GISTs had wild type, KIT exon 9, or KIT exon 11 mutations. Hand-foot syndrome was the most common cause of grade III adverse effect (26.1%), followed by anemia (17.4%), and neutropenia (13.0%). During the median 7.5-mo follow-up after sunitinib use, the median PFS and OS of these 23 GIST patients after sunitinib treatment were 8.4 and 14.1 mo, respectively.CONCLUSION: Sunitinib appears to be an effective treatment for Taiwanese with IM-resistant/intolerant GISTs and induced a sustained clinical benefit in more than 50% of Taiwanese advanced GIST patients. (C) 2011 Baishideng. All rights reserved.